1-4 of 4
Neil Johnson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress

Marissa L. Calbert, Gurushankar Chandramouly, Clare M. Adams, Magali Saez-Ayala, Tatiana Kent, Mrityunjay Tyagi, V.S.S. Abhinav Ayyadevara, Yifan Wang, John J. Krais, John Gordon, Jessica Atkins, Monika M. Toma, Stéphane Betzi, Andrew S. Boghossian, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Aaron R. Goldman, Nicole Gorman, Ramkrishna Mitra, Wayne E. Childers, Xavier Graña, Tomasz Skorski, Neil Johnson, Christian Hurtz, Xavier Morelli, Christine M. Eischen, Richard T. Pomerantz
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (5): 683–699.
https://doi.org/10.1158/1535-7163.MCT-23-0487
Published: 02 May 2024
View article titled, 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress
Open the PDF for 4′-Ethynyl-2′-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress in another window
Includes: Supplementary data
Journal Articles

Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations

Pyoung Hwa Park, Tomomi M. Yamamoto, Hua Li, Allen L. Alcivar, Bing Xia, Yifan Wang, Andrea J. Bernhardy, Kristen M. Turner, Andrew V. Kossenkov, Zachary L. Watson, Kian Behbakht, Silvia Casadei, Elizabeth M. Swisher, Paul S. Mischel, Neil Johnson, Benjamin G. Bitler
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (2): 602–613.
https://doi.org/10.1158/1535-7163.MCT-17-0256
Published: 06 February 2020
View article titled, Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations
Open the PDF for Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations in another window
Includes: Supplementary data
Journal Articles

Abstract C75: Overcoming KRAS/LKB1 mutant NSCLC resistance to BET bromodomain inhibitors with gemcitabine or Mcl-1 inhibition

Michael Kahle, Margaret Soucheray, Jeffrey Becker, Eiki Kikuchi, Inés Pulido, Esra Akbay, Camilla Christensen, Wei Qiu, Fatima Al-Shahrour, Neil Johnson, Julián Carretero, Kwok-Kin Wong, Takeshi Shimamura
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C75.
https://doi.org/10.1158/1535-7163.TARG-15-C75
Published: 01 December 2015
View article titled, Abstract C75: Overcoming KRAS/LKB1 mutant NSCLC resistance to BET bromodomain inhibitors with gemcitabine or Mcl-1 inhibition
Journal Articles

Abstract C74: Stabilization of mutant BRCA1 confers PARP inhibitor and platinum resistance.

Neil Johnson, Shawn F. Johnson, Yifan Wang, Andrea Bernhardy, Wei Yao, Young-Eun Choi, Marzia Capelletti, Kristopher Sarosiek, Lisa Moreau, Dipanjan Chowdhury, Joyce Liu, Alan D'Andrea, Alexander Miron, Anneka Wickramanayake, Maria Harrell, Elizabeth M. Swisher, Geoffrey I. Shapiro
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C74.
https://doi.org/10.1158/1535-7163.TARG-13-C74
Published: 01 November 2013
View article titled, Abstract C74: Stabilization of mutant BRCA1 confers PARP inhibitor and platinum resistance.